ClinicalTrials.gg
Not yet recruitingNCT07844603CoPRIMEUpdated Nov 13, 2026

Combined Antiplatelet Strategy in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPRIME)

A Phase 2 interventional study of Aspirin + Clopidogrel and Aspirin in Acute Ischemic Stroke, sponsored by University of Alberta. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by University of Alberta · Phase 2, Interventional, and Treatment

How we know

Updated Nov 13, 2026Now Not yet recruitingStart date moved+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 23 studies testing aspirin in Ischemic Stroke — 7 open to participants now, 7 under way, 2 of them phase 3. Aspirin · Ischemic Stroke.

Planned enrollment
13th of 23
300 · median 400
Started
2027
the only one that year
Phase 2
3 of 23
1 open now
Registered
22nd of 23
by date
Lead sponsor
2 of 23
University of Alberta

Among the 23 studies testing aspirin in Ischemic Stroke, this one is the 13th largest by planned enrollment, is the only one that started in 2027, is one of 3 in phase 2, and was the 22nd registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

7 of the 23 studies testing aspirin in Ischemic Stroke are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing aspirin in Ischemic Stroke, or all of them as a file.
02

Study summary

Strokes are an major cause of disability. The most common stroke is called an "ischemic stroke". These strokes happen when a blood vessel in the brain is blocked by a clot. The blockage decreases blood flow. This damages the brain. To treat stroke, doctors use medicines and procedures to remove the clot.

After patients have a stroke, they may have another one in the first few weeks. Doctors often use aspirin to prevent another stroke. However, more strokes might be prevented if we use aspirin together with a medicine called clopidogrel or with ticagrelor. Aspirin plus clopidogrel or aspirin plus ticagrelor might prevent more clots from forming in the blood. The risk of these medicines are bleeding.

This study will test if using aspirin plus clopidogrel or aspirin plus ticagrelor together for 3 weeks is safe and practical when compared to aspirin alone. Patients will have a chance to join the study soon after they have been treated for a stroke. They will be checked for a low risk of bleeding with a brain scan. The study treatment will be chosen by chance like a coin toss. One third will take aspirin alone. One third will take aspirin and clopidogrel. One a third will take aspirin and ticagrelor. The study team will follow participants for three months.

Read the detailed description

Purpose - The purpose of this study is to assess the safety and efficacy of two different dual antiplatelet treatments (DAPT) versus aspirin alone in patients who have received treatment for acute ischemic stroke.

Hypothesis - We hypothesize that it is safe and feasable to combine a second antiplatelet medication (either ticegrelor or clopidogrel) with standard-of-care for 21 days in patients with acute ischemic stroke with mild to moderate neurological deficits following reperfusion therapy, when initiated within 30 hours of intravenous thrombolysis (IVT) and/or endovascular thrombectomy (EVT).

Justification - Patients who have had an ischemic stroke are at higher risk of having another ischemic stroke. This risk is highest in the first 21 days after a stroke and varies depending on the treatment received.

Currently, doctors give patients the medication aspirin every day, starting 24 hours after stroke treatment, to prevent recurrent stroke. However, some studies have shown that giving another medication, clopidogrel, in addition to aspirin is safe and may work better than aspirin alone at preventing repeat strokes. The combination of aspirin with a medication known as ticagrelor has also been associated with a relative risk reduction for recurrent stroke. Aspirin, clopidogrel, and ticagrelor are a type of medication called an antiplatelet, they work by decreasing clots from forming in the blood. When medications are given together it is called dual antiplatelet treatment (DAPT). The main risk of antiplatelet medications is bleeding.

DAPT is currently used as a standard treatment for patients with transient ischemic attack (TIA) or minor ischemic stroke in whom more aggressive treatment such as thrombolysis or EVT are not appropriate. However it is not known whether DAPT is safe and effective at preventing recurrent ischemic stroke in patients who have received thrombolysis and/or EVT.

Objectives - The primary outcome of this study is to assess feasibility. This will be assessed by the recruitment rate which will be estimated based on the average number of patients recruited per center over 12 months. Other secondary feasibility outcomes will include medication adherence (defined as a yes or a no to the ability to take all the doses of the antiplatelet therapy for 21 days), retention rates (defined as the proportion of participants that complete the 30-day follow-up), and gene (CYP2C19) carrier assessment workflow time. The gene carrier assessment workflow will be assessed in two parts; the time it takes to obtain results from time of randomization as well as the barriers of testing.

Safety will be measured as a secondary outcome. This outcome will be measured based on the proportion of patients with symptomatic intracranial hemorrhage (SICH). This will be defined as worsening of NIHSS ≥4 compared to score at randomization and systemic bleeding associated with a decrease in hemoglobin by 20 g/L.

Secondary clinical outcomes include the proportion of patients with worsening focal neurologic deficit defined as an increase in NIHSS score by ≥4, as well as the proportion of patients with recurrent stroke, deep vein thrombosis, pulmonary embolism, acute coronary syndromes, prevalence of CYP2C19 mutation, atrial fibrillation, and death.

Research Method/Procedures - Patients who have received treatment for an ischemic stroke will first be screened to rule out patients at high risk of bleeding according to the exclusion criteria. Following informed consent, patients at low risk of bleeding will be enrolled into the study within 30 hours after their initial stroke treatment. Enrolled patients will be randomly assigned to the clopidogrel plus aspirin group (300 mg loading dose of clopidogrel plus 160 mg aspirin on day 1; followed by clopidogrel 75 mg plus aspirin 81 mg daily from day 2 - day 21, followed by aspirin 81 mg to be continued if no alternate treatment is indicated), ticagrelor plus aspirin group (On day 1 participants will receive a loading dose of 180mg of ticagrelor plus a 160mg aspirin; followed by 90 mg of ticagrelor twice daily plus aspirin 81 mg from day 2 - day 21), or aspirin alone group (aspirin 81 mg daily). All patients will receive guideline-based stroke care for vascular risk factor control and hospital management.

Inclusion criteria

  1. Participants must be ≥18 years of age at randomization.
  2. Acute non-cardioembolic ischemic stroke treated with reperfusion therapy, defined as intravenous thrombolysis (IVT) and/or endovascular thrombectomy (EVT).
  3. Time from the end of acute reperfusion therapy to randomization ≤ 30 hours.
  4. Mild-to-moderate deficit is defined as a National Institutes of Health Stroke Scale score ≤10 at the time of randomization.
  5. At least one non-contrast CT scan completed post-reperfusion therapy and prior to randomization.
  6. Signed informed consent from the patient or surrogate decision maker.

Exclusion criteria

  1. Post-reperfusion CT scan shows cerebral parenchymal hematoma (parenchymal hematoma type 1 and 2) or confluent hematoma (Hemorrhagic Infarction type 2). Petechial hemorrhagic transformation (Hemorrhagic Infarction type 1) and contrast staining alone will be included.
  2. Any known disorder associated with a significantly increased risk of bleeding.
  3. Anticoagulation is required for any indication other than DVT prophylaxis.
  4. Evidence-based indication for dual antiplatelet therapy.
  5. Planned surgical intervention in the next 30 days includes but is not limited to carotid endarterectomy, where dual antiplatelet therapy is not indicated, and carotid stenting, where single antiplatelet therapy is not used.
  6. History of non-traumatic intracranial or subarachnoid hemorrhage within the last 1 year.
  7. Intracranial tumour, arteriovenous malformation or aneurysm;
  8. Intracranial or spinal cord surgery within three months;
  9. Gastrointestinal or urinary tract hemorrhage within the previous 21 days
  10. Coagulation disorder, thrombocytopenia \<100, 000/mm3, and Prothrombin time INR ≥1.8
  11. Index stroke is caused by infective endocarditis, dissection, systematic or central nervous system vasculitis
  12. History of active malignancy being treated or life expectancy ≤ 90 days
  13. Allergy to clopidogrel, ticagrelor or aspirin
  14. Pregnancy or lactation
  15. The presence of a major co-morbid illness that would make it unlikely that the participant will be able to complete follow-up
  16. Conditional co-enrolment permitted except for ACT-42 trial (NoNO-42 Trial in Acute Ischemic Stroke).

Participant follow up visits:

Day 1 and Day 7/Discharge: The study team member will visit the patient and complete a National Institute of Health Stroke Scale (NIHSS) assessment (uploaded to document section) and screen the patient for adverse events. Follow up imaging and vital signs will be done as per standard of care and collected by the study team from the electronic medical records system. Concomitant medications, study drug compliance, and adverse events will be recorded from the electronic medical records system. At time of randomization the study team will also collect buccal swap samples and complete the CYP2C19 gene test.

Day 30±6: A study team member will call patients (or visit if patient is admitted to hospital) to complete a Modified Rankin Scale assessment (mRS), EQ-5D-5L assessment, screen the patient for adverse events, and assess concomitant and study drug medication usage.

Day 90±15: Whenever possible, patients will be seen in person at the Stroke Prevention Clinic. A study team member will complete a Modified Rankin Scale assessment (mRS), EQ-5D-5L assessment, and screen the patient for adverse events. Vital signs and neuro imaging (CT or MRI scan) will be done as per standard of care and collected from the electronic medical records system.

Plan for Data Analysis - We will enrol 300 patients at a 1:1:1 ratio. 100 patients will be enrolled in the clopidogrel plus aspirin group, 100 patients will be enrolled in the ticagrelor plus aspirin group, and 100 patients will be enrolled in the aspirin-alone group. In patients with moderate (10 ≤ NIHSS) ischemic stroke dual antiplatelet is associated with a 0.1-0.9% risk of intracranial hemorrhage thus a reliable sample would be 100 in each group.

03

Conditions studied

  • Acute Ischemic Stroke

Keywords

  • intravenous thrombolysis
  • endovascular thrombectomy
  • recurrent stroke
  • Anti-platelet Medication
  • Aspirin
  • Clopidogrel
  • Acute ischemic stroke
  • Ticagrelor
04

Who can participate

The criteria were revised on the registry on Nov 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be ≥18 years of age at randomization.
  2. Acute non-cardioembolic ischemic stroke treated with reperfusion therapy, defined as intravenous thrombolysis (IVT) and/or endovascular thrombectomy (EVT).
  3. Time from the end of acute reperfusion therapy to randomization ≤ 30 hours.
  4. Mild-to-moderate deficit is defined as a National Institutes of Health Stroke Scale score ≤10 at the time of randomization.
  5. At least one non-contrast CT scan completed post-reperfusion therapy and prior to randomization.
  6. Signed from the patient or surrogate decision maker.

Exclusion criteria

Exclusion criteria

  1. Post-reperfusion CT scan shows cerebral parenchymal hematoma (parenchymal hematoma type 1 and 2) or confluent hematoma (Hemorrhagic Infarction type 2). Petechial hemorrhagic transformation (Hemorrhagic Infarction type 1) and contrast staining alone will be included.
  2. Any known disorder associated with a significantly increased risk of bleeding.
  3. Anticoagulation is required for any indication other than DVT prophylaxis.
  4. Evidence-based indication for dual antiplatelet therapy.
  5. Planned surgical intervention in the next 30 days includes but is not limited to carotid endarterectomy, where dual antiplatelet therapy is not indicated, and carotid stenting, where single antiplatelet therapy is not used.
  6. History of non-traumatic intracranial or subarachnoid hemorrhage within the last 1 year.
  7. Intracranial tumour, arteriovenous malformation or aneurysm;
  8. Intracranial or spinal cord surgery within three months;
  9. Gastrointestinal or urinary tract hemorrhage within the previous 21 days
  10. Coagulation disorder, thrombocytopenia \<100, 000/mm3, and INR ≥1.8
  11. Index stroke is caused by infective endocarditis, dissection, systematic or central nervous system vasculitis
  12. History of active being treated or ≤ 90 days
  13. Allergy to clopidogrel, ticagrelor or aspirin
  14. Pregnancy or lactation
  15. The presence of a major co-morbid illness that would make it unlikely that the participant will be able to complete follow-up
  16. Conditional co-enrolment permitted except for ACT-42 trial (NoNO-42 Trial in Acute Ischemic Stroke).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Active comparator
    Aspirin Group

    Drug: Aspirin

  • Experimental
    Clopidogrel Dual Antiplatelet Group

    Drug: Aspirin + Clopidogrel

  • Experimental
    Ticagrelor Dual Antiplatelet Group

    Drug: Aspirin + Ticagrelor

Interventions

  • DrugAspirin + Clopidogrel

    Drug pages: AspirinStudies of AspirinAspirin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ClopidogrelStudies of ClopidogrelClopidogrel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Enrolled patients with acute ischemic stroke will be randomly assigned to the clopidogrel plus aspirin group (300 mg loading dose of clopidogrel plus 160 mg aspirin on day 1; followed by clopidogrel 75 mg plus aspirin 81 mg daily from day 2-day 21, followed by aspirin 81 mg to be continued if no alternate treatment is indicated).

    Also known as: Dual antiplatelet treatment

  • Aspirin 81 mg once daily alone

  • DrugAspirin + Ticagrelor

    Drug pages: AspirinStudies of AspirinAspirin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TicagrelorStudies of TicagrelorTicagrelor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Enrolled patients with acute ischemic stroke will be randomly assigned to the ticagrelor plus aspirin group (a loading dose 180mg of ticagrelor plus a 160mg aspirin; followed by 90 mg of ticagrelor twice daily plus aspirin 81 mg from day 2 - day 21, followed by aspirin 81 mg to be continued if no alternate treatment is indicated).

06

What researchers measure

Primary outcomes

  1. Safety

    Safety will be assessed as a proportion of patients with symptomatic hemorrhagic transformation, defined as worsening of NIHSS ≥4 compared to NIHSS at the time of randomization and hemorrhage is attributable to the antiplatelet therapy by the treatment team.

    Time frame: 90 days

  2. Feasibility

    Feasibility will be assessed as a proportion of recruited patients complete the study intervention for 21 days.

    Time frame: 21 days

Secondary outcomes

  1. Early Neurological Deterioration

    Secondary outcome measures include the proportion of patients with worsening focal neurologic deficit by NIHSS ≥4 at day seven or discharge not due to hemorrhagic transformation or any intracranial hemorrhage. Worsening will be defined as a change in NIHSS compared to NIHSS at the time of randomization.

    Time frame: 7 days

  2. Recurrent Stroke

    Time frame: 90 days

  3. Death

    Time frame: 90 days

  4. Non-Stroke Thrombotic events

    Time frame: 90 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — IPD will be available to investigators in consultation with the principal investigators

Supporting information: Study protocol, Informed consent form

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2030, 47 months later.

Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 47 months is above that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: start Sep 2025 → Jan 2027, primary completion Jul 2026 → Dec 2030 and completion Jul 2026 → Dec 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 28, 2026
StartEst.
Jan 1, 2027was Sep 2025
Primary completionEst.
Dec 31, 2030was Jul 2026
CompletionEst.
Dec 31, 2030was Jul 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Not yet recruiting
changed Nov 13, 2026
Start date
Sep 2, 2025→Jan 1, 2027
Nov 13, 2026
Primary completion
Jul 13, 2026→Dec 31, 2030
Nov 13, 2026
Study completion
Jul 13, 2026→Dec 31, 2030
Nov 13, 2026
Enrollment
3 (actual)→300 (estimated)
Nov 13, 2026
Eligibility
6 inclusion criteria edited, 1 removed; 4 exclusion criteria edited, 2 added, 2 removed
What changed in the criteria
Inclusion criteria
  • EditedParticipants must be >≥18 years of age at the time of randomization.
  • EditedAcute non-cardioembolic ischemic stroke in the anterior circulation treated with reperfusion therapy, defined as intravenous thrombolysis (IVT) and/or endovascular thrombectomy (EVT).
  • EditedTime from the end of acute reperfusion therapy to randomization ≤ 2430 hours.
  • EditedMild -to -moderate deficit is defined as a National InstituteInstitutes of Health stroke scale ofStroke Scale score ≤1110 at the time of randomization.
  • EditedAt least one non-contrast CT scan completed post -reperfusion therapy and prior to randomization without any hemorrhage (including hemorrhagic infarction) and/or contrast extravasation.
  • RemovedPremorbid mRS less than or equal to 2
  • EditedSigned informed consent from the patient or legally authorized representativesurrogate decision maker.
Exclusion criteria
  • AddedPost-reperfusion CT scan shows cerebral parenchymal hematoma (parenchymal hematoma type 1 and 2) or confluent hematoma (Hemorrhagic Infarction type 2). Petechial hemorrhagic transformation (Hemorrhagic Infarction type 1) and contrast staining alone will be included.
  • RemovedPost-reperfusion CT scan ASPECT score <8.
  • EditedPlanned surgical intervention in the next 9030 days includes but is not limited to carotid endarterectomy, where dual antiplatelet therapy is not indicated, and carotid stenting, where single antiplatelet therapy is not used.
  • EditedHistory of non-traumatic intracranial or subarachnoid hemorrhage within the last 1 year.
  • EditedAllergy to clopidogrel, ticagrelor or aspirin
  • EditedPregnancy or lactation
  • RemovedParticipation in another clinical trial.
  • AddedConditional co-enrolment permitted except for ACT-42 trial (NoNO-42 Trial in Acute Ischemic Stroke).
Nov 13, 2026
Interventions
Added Drug: Aspirin + Clopidogrel·Drug: Aspirin + Ticagrelor; removed Drug: aspirin + clopidogrel. Arm changed Dual Antiplatelet Group→Clopidogrel Dual Antiplatelet Group. Arms added: Ticagrelor Dual Antiplatelet Group
Nov 13, 2026
Contact
Study contact now listed: added f•••@ualberta.ca · •••4366; added a•••@ualberta.ca · •••4366. See the current contact
Nov 13, 2026
Registered
First appeared on the registry
Sep 28, 2026
Show all 2 updates
  1. Nov 13, 2026
    Completed→Not yet recruiting
    Start date Sep 2, 2025→Jan 1, 2027
    Primary completion Jul 13, 2026→Dec 31, 2030
    Study completion Jul 13, 2026→Dec 31, 2030
    Enrollment 3 (actual)→300 (estimated)
    Eligibility 6 inclusion criteria edited, 1 removed; 4 exclusion criteria edited, 2 added, 2 removed
    What changed in the criteria
    Inclusion criteria
    • EditedParticipants must be >≥18 years of age at the time of randomization.
    • EditedAcute non-cardioembolic ischemic stroke in the anterior circulation treated with reperfusion therapy, defined as intravenous thrombolysis (IVT) and/or endovascular thrombectomy (EVT).
    • EditedTime from the end of acute reperfusion therapy to randomization ≤ 2430 hours.
    • EditedMild -to -moderate deficit is defined as a National InstituteInstitutes of Health stroke scale ofStroke Scale score ≤1110 at the time of randomization.
    • EditedAt least one non-contrast CT scan completed post -reperfusion therapy and prior to randomization without any hemorrhage (including hemorrhagic infarction) and/or contrast extravasation.
    • RemovedPremorbid mRS less than or equal to 2
    • EditedSigned informed consent from the patient or legally authorized representativesurrogate decision maker.
    Exclusion criteria
    • AddedPost-reperfusion CT scan shows cerebral parenchymal hematoma (parenchymal hematoma type 1 and 2) or confluent hematoma (Hemorrhagic Infarction type 2). Petechial hemorrhagic transformation (Hemorrhagic Infarction type 1) and contrast staining alone will be included.
    • RemovedPost-reperfusion CT scan ASPECT score <8.
    • EditedPlanned surgical intervention in the next 9030 days includes but is not limited to carotid endarterectomy, where dual antiplatelet therapy is not indicated, and carotid stenting, where single antiplatelet therapy is not used.
    • EditedHistory of non-traumatic intracranial or subarachnoid hemorrhage within the last 1 year.
    • EditedAllergy to clopidogrel, ticagrelor or aspirin
    • EditedPregnancy or lactation
    • RemovedParticipation in another clinical trial.
    • AddedConditional co-enrolment permitted except for ACT-42 trial (NoNO-42 Trial in Acute Ischemic Stroke).
    Interventions Added Drug: Aspirin + Clopidogrel·Drug: Aspirin + Ticagrelor; removed Drug: aspirin + clopidogrel. Arm changed Dual Antiplatelet Group→Clopidogrel Dual Antiplatelet Group. Arms added: Ticagrelor Dual Antiplatelet Group
    Contact Study contact now listed: added f•••@ualberta.ca · •••4366; added a•••@ualberta.ca · •••4366. See the current contact
    + 6 other changes: index terms, identifiers, verification date, responsible party, description and conditions
  2. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07844603
Responsible party
Sponsor
First posted
Sep 28, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Nov 13, 2026

Study contacts

Paige Lesoway
Contact
fairall@ualberta.ca
7804074366
Alexandra Buhler
Contact
abuhler1@ualberta.ca
780-407-4366
Brian Buck
principal investigator · University of Alberta
Mahesh Kate
principal investigator · University of Alberta

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aspirin · Clopidogrel · Ticagrelor

Start the discussion